EMEND — aprepitant capsule
EMEND — aprepitant
Physicians Total Care, Inc.
EMEND, in combination with other antiemetic agents, is indicated for the:
- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
- prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) [see Dosage and Administration (2.1)].
EMEND is indicated for the prevention of postoperative nausea and vomiting [see Dosage and Administration (2.2)].
EMEND has not been studied for the treatment of established nausea and vomiting.
Chronic continuous administration is not recommended [see Warnings and Precautions (5.5)].
Capsules of EMEND (aprepitant) are given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose of EMEND is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3.
EMEND may be taken with or without food.
EMEND (fosaprepitant dimeglumine) for Injection (115 mg) is a prodrug of aprepitant and may be substituted for oral EMEND (125 mg), 30 minutes prior to chemotherapy, on Day 1 only of the CINV regimen as an intravenous infusion administered over 15 minutes.
In clinical studies with EMEND, the following regimen was used for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
|Day 1||Day 2||Day 3||Day 4|
|EMEND||125 mg orally||80 mg orally||80 mg orally||none|
|Dexamethasone||12 mg orally||8 mg orally||8 mg orally||8 mg orally|
|Ondansetron||32 mg I.V.||none||none||none|
In a clinical study with EMEND, the following regimen was used for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
|Day 1||Day 2||Day 3|
|EMEND||125 mg orally||80 mg orally||80 mg orally|
|Dexamethasone||12 mg orally||none||none|
|Ondansetron||2 x 8 mg orally||none||none|
The recommended oral dosage of EMEND is 40 mg within 3 hours prior to induction of anesthesia.
EMEND may be taken with or without food.
No dosage adjustment is necessary for the elderly.
No dosage adjustment is necessary for patients with renal impairment or for patients with end stage renal disease (ESRD) undergoing hemodialysis.
No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic impairment (Child-Pugh score >9).
For additional information on dose adjustment for corticosteroids when coadministered with EMEND, see Drug Interactions (7.1).
Refer to the full prescribing information for coadministered antiemetic agents.
- Capsules EMEND 40 mg are opaque, hard, gelatin capsules, with white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink on the body.
- Capsules EMEND 80 mg are white, opaque, hard, gelatin capsules, with “461” and “80 mg” printed radially in black ink on the body.
- Capsules EMEND 125 mg are opaque, hard, gelatin capsules, with white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
EMEND is contraindicated in patients who are hypersensitive to any component of the product.
EMEND is a dose-dependent inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A4). EMEND should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions [see Drug Interactions (7.1)].
EMEND (aprepitant), a dose-dependent inhibitor of CYP3A4, should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4. Moderate inhibition of CYP3A4 by aprepitant, 125 mg/80 mg regimen, could result in elevated plasma concentrations of these concomitant medications.
Weak inhibition of CYP3A4 by a single 40 mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medications that are primarily metabolized through CYP3A4 to a clinically significant degree.
When aprepitant is used concomitantly with another CYP3A4 inhibitor, aprepitant plasma concentrations could be elevated. When EMEND is used concomitantly with medications that induce CYP3A4 activity aprepitant plasma concentrations could be reduced and this may result in decreased efficacy of EMEND [see Drug Interactions (7.1)].
Chemotherapy agents that are known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine and vincristine. In clinical studies, EMEND (125 mg/80 mg regimen) was administered commonly with etoposide, vinorelbine, or paclitaxel. The doses of these agents were not adjusted to account for potential drug interactions.
In separate pharmacokinetic studies no clinically significant change in docetaxel or vinorelbine pharmacokinetics was observed when EMEND (125 mg/80 mg regimen) was co-administered.
Due to the small number of patients in clinical studies who received the CYP3A4 substrates vinblastine, vincristine, or ifosfamide, particular caution and careful monitoring are advised in patients receiving these agents or other chemotherapy agents metabolized primarily by CYP3A4 that were not studied [see Drug Interactions (7.1)].
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.